Robert Califf, FDA commissioner (Michael Brochstein/Sipa USA/Sipa via AP Images)
April 21, 2022 01:34 PM EDTUpdated April 22, 04:59 PM
FDA+
Coronavirus

Biotech, aca­d­e­m­ic lead­ers en­cour­age FDA to con­sid­er T-cell as­sess­ment in Covid-19 vac­cine tri­als

Tyler Patchen

News Reporter

More than 60 sig­na­to­ries sent a let­ter to the FDA’s Robert Califf and Pe­ter Marks on Thurs­day urg­ing the agency to in­clude a rec­om­men­da­tion for …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Up­dat­ed: With cost-cut­ting un­der­way, Bris­tol My­ers rais­es guid­ance, touts Phase 3 win and scraps an­oth­er

Bris­tol My­ers restarts ra­dio­phar­ma­ceu­ti­cal Phase 3 tri­al, but de­lays read­out by one year

Among phar­ma CEOs, the IRA now and the IRA lat­er get very dif­fer­ent re­ac­tions

Eu­ro­pean drug reg­u­la­tor re­jects Alzheimer's drug Leqem­bi, cit­ing safe­ty con­cerns

An­drew Left, short sell­er who cam­paigned against Valeant, is ac­cused of fraud by SEC

sponsored

Crit­i­cal Junc­tures in Gene Ther­a­py Clin­i­cal Ma­te­r­i­al Man­u­fac­tur­ing: Where Do I Start? And Will It Work?

A service from the Financial Times